Mannose‐Functionalized Mesoporous Silica Nanoparticles for Efficient Two‐Photon Photodynamic Therapy of Solid Tumors

Gary‐Bobo, Magali; Mir, Y.; Rouxel, Cédric; Brevet, David; Basile, Ilaria; Maynadier, Marie; Vaillant, Ophélie; Mongin, Olivier; Blanchard‐Desce, Mireille; Morére, Alain; Garcia, Marcel; Durand, Jean‐Olivier; Raehm, Laurence

doi:10.1002/ange.201104765

Cited by 97 publications

(82 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[4][5][6][7] While part of the scientific community creatively advances towards the engineering of porous silica nanostructures, others are acting in a proactive approach by considering environmental and toxicological effects of nano-based silica materials. In the latter context, several in vitro citotoxicity assays indicated a very high biocompatibility of porous silica nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

Suppression of the hemolytic effect of mesoporous silica nanoparticles after protein corona interaction: independence of the surface microchemical environment

Paula¹,

Martinez²,

Júnior³

et al. 2012

J. Braz. Chem. Soc.

View full text Add to dashboard Cite

Nanopartículas mesoporosas de sílica são conhecidas por induzirem hemólise de células vermelhas do sangue (RBCs) humano quando ensaios de citotoxicidade são feitos em solução-tampão de fosfato (PBS). Entretanto, em uma abordagem mais realista, a presença de biomoléculas do plasma sanguíneo precisa ser considerada em qualquer avaliação nanotoxicológica de nanopartículas porosas de SiO 2 quando se objetiva a sua utilização em aplicações biomédicas através de administração intravenosa. Nesse contexto, demonstrou-se neste trabalho que nanopartículas porosas de sílica não induzem nenhum efeito citotóxico em células vermelhas do sangue quando ensaios de hemólise são feitos na presença de plasma sanguíneo, independentemente da carga superficial (positiva ou negativa) da nanopartícula. A ausência de hemólise está principalmente associada à adsorção de proteínas do plasma sobre a superfície das nanopartículas, levando à formação de um recobrimento proteico estável (denominado protein corona ou PC) que blinda o ambiente microquímico original das nanopartículas.Mesoporous silica nanoparticles are known to induce the hemolysis of human red blood cells (RBCs) when citotoxicity assays are performed in a phosphate buffer solution (PBS). However, in a more realistic approach, the presence of blood plasma biomolecules must be considered in any nanotoxicological evaluation of porous SiO 2 nanoparticles when biomedical applications through intravenous administration are aimed. In this context, it is demonstrated in this work that porous silica nanoparticles do not induce any cytotoxic effect on RBCs when hemolysis assay is done in the presence of blood plasma, regardless the surface charge (positive or negative) of the nanoparticle. The absence of hemolysis is mainly associated with the adsorption of plasma proteins on the nanoparticle surface, which leads to the formation of a stable protein coating (called protein corona or PC) that shields the original microchemical environment of bare nanoparticles.Keywords: nanoparticles, SiO 2 , mesopores, hemolytic effect, protein corona IntroductionSince porous silica nanoparticles were elected as possible protagonists in a future revolution of several medical processes of theranosis, they have been widely studied during the last decade through the host-guest approach, thus resulting in promising perspectives mainly in the areas of detection 1-3 and treatment of tumors. [4][5][6][7] While part of the scientific community creatively advances towards the engineering of porous silica nanostructures, others are acting in a proactive approach by considering environmental and toxicological effects of nano-based silica materials. In the latter context, several in vitro citotoxicity assays indicated a very high biocompatibility of porous silica nanoparticles. [8][9][10] However, a desirable in vivo biocompatibility is not straightforward. For instance, it is well known that amorphous silica particles induce toxicity on human red blood cells (RBCs) and, consequently, this test is being used as a ke...

show abstract

Section: Introductionmentioning

confidence: 99%

Suppression of the hemolytic effect of mesoporous silica nanoparticles after protein corona interaction: independence of the surface microchemical environment

Paula¹,

Martinez²,

Júnior³

et al. 2012

J. Braz. Chem. Soc.

View full text Add to dashboard Cite

show abstract

“…The MSN1-mannose nanoparticles were investigated in human breast and colon cancer cell lines, as well as xenograft tumour mice and shown to bind to lectins overexpressed in cancer cells. They have large two-photon absorption crosssections up to 8 MGM (~ 1200 GM per individual PS molecule) and therefore might be a promising tool for 2P-PDT cancer therapy [11]. A means proposed to achieve more efficient light delivery and improved photosensitization for two-photon PDT was based on polymer nanoparticles (~50 nm diameter) conjugated with the PS tetraphenylporphyrin.…”

Section: Figure 5 Examples Of Pss Designed To Have High Two-photon Abmentioning

confidence: 99%

“…The highly reactive oxygen species (ROS) have the ability to locally destroy cancerous tissue in a patient [4,5,[7][8][9][10][11][12]. In the clinic PDT treatment commonly consists of two stages ( Figure 1B).…”

Section: Introduction To Pdtmentioning

confidence: 99%

New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons

Scherer

Bisby²,

Botchway³

et al. 2017

ACAMC

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an alternative cancer treatment to conventional surgery, radiotherapy and chemotherapy. It is based on activating a drug with light that triggers the generation of cytotoxic species that promote tumour cell killing. At present, PDT is mainly used in the treatment of wet age-related macular degeneration, for precancerous conditions of the skin (e.g. actinic keratosis) and in the palliative care of advanced cancers, for instance of the bladder or the oesophagus. Due to a lack of phase III clinical trials and limitations of light penetration to deeper lying tumours (in excess of 1 cm), PDT is still not used as a first line cancer treatment, which is surprising given the first clinical trials by Dougherty's group dating back to the 1970's. However research continues to demonstrate the potential benefits of PDT and the need to stimulate funding and uptake of clinical studies using next generation photosensitizers offering advanced targeted delivery, improved photodynamic dose combined with modern light delivery technologies. This review surveys the available PDT treatments and emerging novel developments in the field with a particular focus on two-photon techniques that are anticipated to improve the effectiveness of PDT in tissues at depth and on next generation drugs that work without the need of the presence of oxygen for photosensitization making them effective where hypoxia has taken hold.

show abstract

“…[31] The as-prepared nanomaterials were labeled MA and MF, respectively for the mesoporous silica-azobenzene and mesoporous silicafluorophore modification, whereas the co-condensation of both the azobenzene and the fluorophore with different proportions led to MAF-x (see Table 1). …”

Section: Introductionmentioning

confidence: 99%

Two‐Photon‐Triggered Drug Delivery in Cancer Cells Using Nanoimpellers

et al. 2013

Self Cite

View full text Add to dashboard Cite

Mannose‐Functionalized Mesoporous Silica Nanoparticles for Efficient Two‐Photon Photodynamic Therapy of Solid Tumors

Cited by 97 publications

References 28 publications

Suppression of the hemolytic effect of mesoporous silica nanoparticles after protein corona interaction: independence of the surface microchemical environment

Suppression of the hemolytic effect of mesoporous silica nanoparticles after protein corona interaction: independence of the surface microchemical environment

New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons

Two‐Photon‐Triggered Drug Delivery in Cancer Cells Using Nanoimpellers

Contact Info

Product

Resources

About